Compare DRUG & DHIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DRUG | DHIL |
|---|---|---|
| Founded | 2019 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 364.8M | 319.2M |
| IPO Year | N/A | 1995 |
| Metric | DRUG | DHIL |
|---|---|---|
| Price | $90.99 | $170.30 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $104.00 | N/A |
| AVG Volume (30 Days) | ★ 296.8K | 41.3K |
| Earning Date | 02-13-2026 | 02-25-2026 |
| Dividend Yield | N/A | ★ 3.53% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 17.21 |
| Revenue | N/A | ★ $149,665,296.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.86 |
| Revenue Growth | N/A | ★ 2.65 |
| 52 Week Low | $23.18 | $114.11 |
| 52 Week High | $123.75 | $171.43 |
| Indicator | DRUG | DHIL |
|---|---|---|
| Relative Strength Index (RSI) | 59.47 | 76.86 |
| Support Level | $85.65 | $169.76 |
| Resistance Level | $92.00 | $171.38 |
| Average True Range (ATR) | 9.31 | 0.89 |
| MACD | 0.01 | -1.46 |
| Stochastic Oscillator | 37.59 | 54.01 |
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
Diamond Hill Investment Group Inc sponsors, markets, and provides investment advisory and related services to various U.S. and foreign clients including mutual funds, separate accounts, and private investment funds. The company's objective is to fulfill a fiduciary duty to clients and secondary objectives to achieve an adequate long-term return for shareholders. The company generates its revenue from Investment advisory and fund administration fees.